



December 6, 2017

PositiveID Commences Production of Next Generation Caregiver Thermometer with Bluetooth Capability

Bluetooth-enabled Caregiver Device Holds Potential to Disrupt the \$1 Billion Thermometry Market

DELRAY BEACH, Fla., Dec. 06, 2017 (GLOBE NEWSWIRE) -- [PositiveID Corporation](#) (OTC:PSID), a life sciences company focused on detection and diagnostics, is excited to announce that its Thermomedics subsidiary has commenced production of its disruptive, next generation Caregiver® thermometer with Bluetooth® capability. Caregiver with Bluetooth will be commercially available in January 2018.

Management believes its newest manifestation of the Caregiver product line is an important design advancement. The new device can connect wirelessly to electronic health records systems and patient monitoring stations in hospitals to transmit temperature readings automatically into a patient's record. According to recent research by MarketsandMarkets, the Bluetooth Smart and Smart Ready market is expected to be worth \$5.34 billion by 2023. Product teams able to elevate next generation devices to take advantage of this trend often experience a corresponding increase in market adoption.

"Incorporating wireless communication of temperature readings is a logical next step for our Caregiver product," says Gary O'Hara, Chief Technology Officer of Thermomedics. "By offering hospitals and clinics the ability to connect and transmit data seamlessly to patient monitoring stations, we eliminate extra steps for healthcare professionals, enabling them to spend more time on patient care, decreasing the likelihood of errors."

PositiveID's FDA-cleared Caregiver is a professional-grade, infrared thermometer capable of delivering an oral-equivalent temperature directly from the forehead in one to two seconds.

The lack of skin contact and absence of probe cover supplies eliminate two chief concerns of healthcare facilities related to thermometry: the risk of cross-contamination of highly-infectious diseases such as Ebola, and unnecessary costs related to probe covers - as much as \$0.10 per temperature, or an estimated \$250 per year per device.

PositiveID executives believe its next generation Bluetooth-enabled model holds the potential to boost adoption of the Caregiver line to take advantage of the growing use of infrared thermometry, which is the fastest growing segment of the \$1 billion global temperature monitoring device market.

About PositiveID Corporation

PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit <http://www.psidcorp.com>, or connect with PositiveID on [Twitter](#), [Facebook](#) or [LinkedIn](#).

Statements about PositiveID's future expectations, including the likelihood that the Bluetooth-enabled Caregiver device holds the potential to disrupt the \$1 billion thermometry market; the likelihood that the Bluetooth-enabled Caregiver will be commercially available in January 2018; the likelihood that the Bluetooth Smart and Smart Ready market is expected to be worth \$5.34 billion by 2023; the likelihood that product teams able to elevate next generation devices to take advantage of this trend often experience a corresponding increase in market adoption; the likelihood that Caregiver can offer savings of \$250 or more per year per device in probe cover supplies alone; the likelihood that the next generation Bluetooth-enabled model holds the potential to boost adoption of the Caregiver line to take advantage of the growing use of infrared thermometry, which is the fastest growing segment of the \$1 billion global temperature monitoring device market; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to attract new customers and retain existing customers; the Company's ability to target the professional healthcare market; the Company's ability to raise capital; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." The Company undertakes no obligation to update or

release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

PositiveID Corporation
Allison Tomek
(561) 805-8044

atomek@psidcorp.com

 Primary Logo

Source: PositiveID Corporation

News Provided by Acquire Media